Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Res Psychother ; 27(1)2024 Mar 14.
Article in English | MEDLINE | ID: mdl-38497293

ABSTRACT

Internationally, there is ongoing concern about accessibility to mental health care and training. The goal of this study was to explore commonalities and differences within models of clinical psychology and psychotherapy in Ontario, Canada, and Lombardia, Italy, respectively, to inform improvements to the accessibility of mental health care and training. Using key informant sampling, we recruited ten students and professionals in Italy and Canada who study or work in psychology for semi-structured interviews. We analyzed the interview content using an inductive approach for thematic analysis within countries and meta-theme analysis across countries. The findings indicated three cross-national meta-themes: the need to integrate evidence with practice, the limited accessibility of training for students and treatment for patients, and the importance of the quality of training programs. Despite some differences regarding the amount of scientific training, personal therapy for trainees, and the prominence of cultural diversity training, Canadian and Italian psychology professionals and students shared experiences of psychotherapy practice and clinical psychology training. The three cross-national meta-themes indicate which issues in training and practice may be relevant worldwide and where to focus resources. The findings can inform international collaborations regarding training model structures that may increase access to psychology training and may increase consensus on professional recognition standards to improve mobility for professionals. These changes could reduce barriers to mental healthcare services for patients.

2.
Int J Mol Sci ; 24(2)2023 Jan 11.
Article in English | MEDLINE | ID: mdl-36674949

ABSTRACT

Prostate cancer is the most common cancer in men, with over 52,000 new cases diagnosed every year. Diagnostics and early treatment are potentially hindered by variations in screening protocols, still largely reliant on serum levels of acid phosphatase and prostate-specific antigen, with tumour diagnosis and grading relying on histopathological examination. Current treatment interventions vary in terms of efficacy, cost and severity of side effects, and relapse can be aggressive and resistant to the current standard of care. For these reasons, the scientific community is looking for new chemotherapeutic agents. This review reports compounds and extracts derived from marine organisms as a potential source of new drugs against prostate cancer. Whilst there are several marine-derived compounds against other cancers, such as multiple myeloma, leukemia, breast and lung cancer, already available in the market, the presently collated findings show how the marine environment can be considered to hold potential as a new drug source for prostate cancer, as well. This review presents information on compounds presently in clinical trials, as well as new compounds/extracts that may enter trials in the future. We summarise information regarding mechanisms of action and active concentrations.


Subject(s)
Biological Products , Prostatic Neoplasms , Male , Humans , Biological Products/pharmacology , Biological Products/therapeutic use , Prostatic Neoplasms/pathology , Prostate-Specific Antigen , Aquatic Organisms
3.
Mol Cell Biol ; 32(19): 3802-13, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22801374

ABSTRACT

Vascular endothelial growth factors (VEGFs) activate three receptor tyrosine kinases, VEGFR-1, -2, and -3, which regulate angiogenic and lymphangiogenic signaling. VEGFR-2 is the most prominent receptor in angiogenic signaling by VEGF ligands. The extracellular part of VEGF receptors consists of seven immunoglobulin homology domains (Ig domains). Earlier studies showed that domains 2 and 3 (D23) mediate ligand binding, while structural analysis of dimeric ligand/receptor complexes by electron microscopy and small-angle solution scattering revealed additional homotypic contacts in membrane-proximal Ig domains D4 and D7. Here we show that D4 and D7 are indispensable for receptor signaling. To confirm the essential role of these domains in signaling, we isolated VEGFR-2-inhibitory "designed ankyrin repeat proteins" (DARPins) that interact with D23, D4, or D7. DARPins that interact with D23 inhibited ligand binding, receptor dimerization, and receptor kinase activation, while DARPins specific for D4 or D7 did not prevent ligand binding or receptor dimerization but effectively blocked receptor signaling and functional output. These data show that D4 and D7 allosterically regulate VEGFR-2 activity. We propose that these extracellular-domain-specific DARPins represent a novel generation of receptor-inhibitory drugs for in vivo applications such as targeting of VEGFRs in medical diagnostics and for treating vascular pathologies.


Subject(s)
Allosteric Site , Vascular Endothelial Growth Factor Receptor-2/chemistry , Vascular Endothelial Growth Factor Receptor-2/metabolism , Allosteric Regulation , Amino Acid Sequence , Animals , Gene Expression , Humans , Protein Structure, Tertiary , Signal Transduction , Vascular Endothelial Growth Factor Receptor-2/genetics
4.
Gynecol Oncol ; 118(1): 81-7, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20421130

ABSTRACT

OBJECTIVE: Ovarian cancer remains the most lethal gynaecological cancer. Various molecular changes have been identified and have shown promise for their diagnostic, prognostic and curative capacity but still need further validation. Among different mechanisms, the present article reviews the importance of epigenetic changes in ovarian cancer. METHODS: Recent literature relevant to epigenetics of ovarian cancer has been reviewed. RESULTS: Greater insight into the epigenetic phenomena DNA methylation, histone modification and posttranscriptional gene downregulation by microRNAs is provided. In addition, the contribution of epigenetic control of gene expression to ovarian oncology is analysed and its potential in the clinic is considered. CONCLUSIONS: Although the epigenetics of ovarian cancer is still in its beginnings, it holds promising potential in early stage ovarian cancer detection, evaluation of prognosis/drug resistance and targeted cancer treatment.


Subject(s)
Ovarian Neoplasms/genetics , Epigenesis, Genetic , Female , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...